Pneumocystis jirovecii pneumonia in non-HIV-infected patients: New risks and diagnostic tools

Current Opinion in Infectious Diseases

Volumn 24, Issue 6, 2011, Pages 534-544

  Reid, Alistair B ^a   Chen, Sharon C A ^b   Worth, Leon J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Diagnosis; Non HIV; PCR; Pneumocystis jirovecii; Risks

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; BENDAMUSTINE; BORTEZOMIB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DASATINIB; DOXORUBICIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TEMOZOLOMIDE; TEMSIROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

ASTROCYTOMA; BACTERIAL TRANSMISSION; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CONNECTIVE TISSUE DISEASE; CROHN DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; ENTERITIS; FUNGAL COLONIZATION; GENE TARGETING; GIANT CELL ARTERITIS; GLIOMA; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPHATIC LEUKEMIA; LYMPHOMA; MOLECULAR DIAGNOSIS; MULTIPLE MYELOMA; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; POLYMYOSITIS; POSITRON EMISSION TOMOGRAPHY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; VALIDATION PROCESS; WEGENER GRANULOMATOSIS;

BETA-GLUCANS; HIV SERONEGATIVITY; HUMANS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 80054966951     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834cac17     Document Type: Review

References (135)

1. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995; 155:2436-2441.
2. Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to Pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005; 128:573-579. (Pubitemid 41140482)
3. Sepkowitz KA. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant 2002; 29:367-371. (Pubitemid 34257709)
4. Hughes WT, Feldman S, Aur RJ, et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36:2004-2009.
5. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994; 21:246-251. (Pubitemid 24078834)
6. Aliouat-Denis CM, Chabe M, Demanche C, et al. Pneumocystis species, coevolution and pathogenic power. Infect Genet Evol 2008; 8:708-726.
7. Montes-Cano MA, Chabe M, Fontillon-Alberdi M, et al. Vertical transmission of Pneumocystis jirovecii in humans. Emerg Infect Dis 2009; 15:125-127.
8. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An Outbreak of Pneumocystis Jiroveci Pneumonia with. 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 44: 1143-1149. (Pubitemid 46651235)
9. Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010; 12:1-10.
10. Hughes WT, Bartley DL, Smith BM. A natural source of infection due to Pneumocystis carinii. J Infect Dis 1983; 147:595. (Pubitemid 13163208)
11. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 51:259-265.
12. Arichi N, Kishikawa H, Mitsui Y, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc 2009; 41:170-172.
13. Hennequin C, Page B, Roux P, et al. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis 1995; 14:122-126.
14. Hocker B, Wendt C, Nahimana A, et al. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005; 11:330-332. (Pubitemid 40239257)
15. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004; 10:1766-1773. (Pubitemid 39319367)
16. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008; 46:966-971. (Pubitemid 351379988)
17. Yazaki H, Goto N, Uchida K, et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88:380-385.
18. Mori S, Cho I, Sugimoto M. A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis. J Rheumatol 2010; 37:1547-1548.
19. Duncan RA, von Reyn CF, Alliegro GM, et al. Idiopathic CD4+ T-lymphocytopenia: four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med 1993; 328:393-398. (Pubitemid 23042287)
20. Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4:371-375. (Pubitemid 23193101)
21. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267:832-837.
22. Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995; 49:135-142.
23. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82:1695-1700. (Pubitemid 23278758)
24. Worth LJ, Dooley MJ, Seymour JF, et al. An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 2005; 92:867-872. (Pubitemid 40462631)
25. Iriart X, Witkowski B, Courtais C, et al. Cellular and cytokine changes in the alveolar environment among immunocompromised patients during Pneumocystis jirovecii infection. Med Mycol 2010; 48:1075-1087.
26. Tasaka S, Kobayashi S, Kamata H, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with Pneumocystis pneumonia. Microbiol Immunol 2010; 54:425-433.
27. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 151:1058-1062.
28. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60:1279-1284.
29. Hu T, Takamoto M, Hida S, et al. IFN-gamma deficiency worsen Pneumocystis pneumonia with Th17 development in nude mice. Immunol Lett 2009; 127:55-59.
30. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891-3897.
31. Enomoto T, Azuma A, Kohno A, et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology 2010; 15:126-131.
32. Kurokawa T, Kaya H, Yoshida T. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J Clin Exp Hematopathol 2010; 50:159-162.
33. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14:696-699.
34. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: A review of 84 cases. Dig Dis Sci 2007; 52:1481-1484. (Pubitemid 46776482)
35. Kamel S, O'Connor S, Lee N, et al. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine and prednisolone. Leuk Lymphoma 2010; 51:797-801.
36. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 2010; 62:1661-1664.
37. Stilling-Vinther MK, Pedersen BS. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol 2011; doi: 10.1111/j.1755-3768.2011.02127.x [Epub ahead of print].
38. Kameda H, Tokuda H, Sakai F, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011; 50:305-313.
39. Estrada S, Garcia-Campos F, Calderon R, et al. Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis. Inflamm Bowel Dis 2009; 15:315-316.
40. Kalyoncu U, KaradagO, Akdogan A, et al. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 2007; 39:475-478. (Pubitemid 46705764)
41. Lahiff C, Khiaron OB, Nolan N, Chadwick GA. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. Ir J Med Sci 2007; 176:309-311. (Pubitemid 350182773)
42. Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011; 13:R112.
43. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132:3-12. (Pubitemid 43381565)
44. Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis: A need for prophylaxis. J Crohns Colitis 2010; 4:606-609.
45. Andres AM, Lopez Santamaria M, Ramos E, et al. The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients. Pediatr Transplant 2010; 14:931-935.
46. Neff RT, Jindal RM, Yoo DY, et al. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88:135-141.
47. Sillaber C, Herrmann H, Bennett K, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily. Eur J Clin Invest 2009; 39:1098-1109.
48. Wondergem MJ, Grunberg K, Wittgen BP, et al. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment. Histopathology 2009; 54:631-633.
49. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol 2004; 22:610-616. (Pubitemid 41095063)
50. Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 2011; 26:2013-2017.
51. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33:629-640. (Pubitemid 32762936)
52. De Castro N, Xu F, Porcher R, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: A case-control study. Clin Microbiol Infect 2010; 16:1375-1377.
53. Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant 2011 [Epub ahead of print].
54. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009; 29:491-496.
55. Hof H, Schnulle P. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 2008; 51 (SUPPL. 1):65-67. (Pubitemid 351678037)
56. Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series. Arthritis Care Res (Hoboken) 2011; 63:761-765.
57. Marie I, Menard JF, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: A series of 279 patients. Semin Arthritis Rheum 2011; 41:48-60.
58. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving antitumor-necrosisfactor- alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010; 25:1732-1738.
59. Lee JC, Bell DC, Guinness RM, Ahmad T. Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis. World J Gastroenterol 2009; 15:1897-1900.
60. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance antitumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10:657-660. (Pubitemid 39276478)
61. Itaba S, Iwasa T, Sadamoto Y, et al. Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease. Dig Dis Sci 2007; 52:1438-1441. (Pubitemid 46776504)
62. Seddik M, Melliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2005; 11:618-620. (Pubitemid 40826354)
63. Pagano L, Fianchi L, Mele L, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117:379-386. (Pubitemid 34451154)
64. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009; 113:3673-3678.
65. Vavricka SR, Halter J, Hechelhammer L, Himmelmann A. Pneumocystis carinii pneumonia in chronic lymphocytic leukaemia. Postgrad Med J 2004; 80:236-238. (Pubitemid 38561406)
66. Poulsen A, Demeny AK, Bang Plum C, et al. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 2001; 37:20-23. (Pubitemid 32613630)
67. Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: A descriptive study. J Infect 2003; 47:19-27. (Pubitemid 36850131)
68. Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006; 25:382-388. (Pubitemid 43885682)
69. Barbounis V, Aperis G, Gambletsas E, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 2005; 25:651-655. (Pubitemid 40470077)
70. Kulke MH, Vance EA. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 1997; 25:215-218. (Pubitemid 127775482)
71. Klippstein A, Schneider CP, Sayer HG, Hoffken K. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol 2003; 129:316-319. (Pubitemid 36791688)
72. Dall'oglio S, D'Amico A, Pioli F, et al. Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. J Neurooncol 2008; 90:315-319.
73. Chalvardjian AM, Grawe LA. A new procedure for the identification of Pneumocystis carinii cysts in tissue sections and smears. J Clin Pathol 1963; 16:383-384.
74. Grocott RG. A stain for fungi in tissue sections and smears using Gomori's methenamine-silver nitrate technique. Am J Clin Pathol 1955; 25:975-979.
75. Alvarez F, Bandi V, Stager C, Guntupalli KK. Detection of Pneumocystis carinii in tracheal aspirates of intubated patients using calcofluor-white (Fungi-Fluor) and immunofluorescence antibody (Genetic Systems) stains. Crit Care Med 1997; 25:948-952. (Pubitemid 27264237)
76. Benfield TL, Prento P, Junge J, et al. Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Chest 1997; 111:1193-1199. (Pubitemid 27200071)
77. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140:1204-1209. (Pubitemid 19276197)
78. Helweg-Larsen J, Jensen JS, Lundgren B. Noninvasive diagnosis of Pneumocystis carinii pneumonia by PCR on oral washes. Lancet 1997; 350:1363. (Pubitemid 28036905)
79. Durand-Joly I, Chabe M, Soula F, et al. Molecular diagnosis of Pneumocystis pneumonia. FEMS Immunol Med Microbiol 2005; 45:405-410. (Pubitemid 41247776)
80. de Oliveira A, Unnasch TR, Crothers K, et al. Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients. Diagn Microbiol Infect Dis 2007; 57:169-176. (Pubitemid 46135875)
81. Larsen HH, Huang L, Kovacs JA, et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004; 189:1679-1683. (Pubitemid 38648297)
82. Vogel MN, Vatlach M, Weissgerber P, et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 2011 [Epub ahead of print]. Recent report summarizing radiology findings in non-HIV-infected patients with PJP.
83. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007; 13:1-7. (Pubitemid 46356234)
84. Sing A, Trebesius K, Roggenkamp A, et al. Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol 2000; 38:1461-1467. (Pubitemid 30216672)
85. Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990; 336:451-453. (Pubitemid 20264212)
86. Weig M, Klinker H, Bogner BH, et al. Usefulness of PCR for diagnosis of Pneumocystis carinii pneumonia in different patient groups. J Clin Microbiol 1997; 35:1445-1449. (Pubitemid 27216810)
87. Ribes JA, Limper AH, Espy MJ, Smith TF. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol 1997; 35:830-835. (Pubitemid 27146519)
88. Gupta R, Mirdha BR, Guleria R, et al. Diagnostic significance of nested polymerase chain reaction for sensitive detection of Pneumocystis jirovecii in respiratory clinical specimens. Diagn Microbiol Infect Dis 2009; 64:381-388.
89. Flori P, Bellete B, Durand F, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004; 53:603-607. (Pubitemid 38932356)
90. Robberts FJ, Liebowitz LD, Chalkley LJ. Polymerase chain reaction detection of Pneumocystis jiroveci: evaluation of 9 assays. Diagn Microbiol Infect Dis 2007; 58:385-392. (Pubitemid 47198402)
91. Bandt D, Monecke S. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jiroveci. Transpl Infect Dis 2007; 9:196-202. (Pubitemid 47231213)
92. Rohner P, Jacomo V, Studer R, et al. Detection of Pneumocystis jirovecii by two staining methods and two quantitative PCR assays. Infection 2009; 37:261-265.
93. Huggett JF, Taylor MS, Kocjan G, et al. Development and evaluation of a realtime PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008; 63:154-159. (Pubitemid 351236483)
94. Cushion MT, Stringer JR. Stealth and opportunism: alternative lifestyles of species in the fungal genus Pneumocystis. Annu Rev Microbiol 2010; 64:431-452.
95. Alanio A, Desoubeaux G, Sarfati C, et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2010; doi: 10.1111/j.1469-0691.2010.03400.x [Epub ahead of print].
96. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011; 5:41-59.
97. Fujisawa T, Suda T, Matsuda H, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology 2009; 14:203-209.
98. Giuntoli D, Stringer SL, Stringer JR. Extraordinarily low number of ribosomal RNA genes in P. carinii. J Eukaryot Microbiol 1994; 41:88S.
99. Pinlaor S, Mootsikapun P, Pinlaor P, et al. PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immuno-compromised patients. Parasitol Res 2004; 94:213-218. (Pubitemid 39371718)
100. Helweg-Larsen J, Jensen JS, Benfield T, et al. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol 1998; 36:2068-2072. (Pubitemid 28277804)
101. Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: A prospective study. Thorax 2003; 58:594-597. (Pubitemid 36808130)
102. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009; 135:655-661.
103. Alvarez-Martinez MJ, Miro JM, Valls ME, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis 2006; 56:153-160. (Pubitemid 44488724)
104. Hauser PM, Bille J, Lass-Florl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol 2011; 49:1872-1878.
105. Chumpitazi BF, Flori P, Kern JB, et al. Characteristics and clinical relevance of the quantitative touch-down major surface glycoprotein polymerase chain reaction in the diagnosis of Pneumocystis pneumonia. Med Mycol 2011; 49:704-713.
106. Dini L, du Plessis M, Frean J, Fernandez V. High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa. J Clin Microbiol 2010; 48:2016-2021.
107. Fillaux J, Malvy S, Alvarez M, et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia. J Microbiol Methods 2008; 75:258-261.
108. Linssen CF, Jacobs JA, Beckers P, et al. Inter-laboratory comparison of three different real-time PCR assays for the detection of Pneumocystis jiroveci in bronchoalveolar lavage fluid samples. J Med Microbiol 2006; 55:1229-1235. (Pubitemid 44373159)
109. de Boer MG, Gelinck LB, van Zelst BD, et al. Beta-D-Glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: A prospective study. J Infect 2011; 62:93-100.
110. Larsen HH, Masur H, Kovacs JA, et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002; 40:490-494. (Pubitemid 34130872)
111. Etoh K. Evaluation of a real-time PCR assay for the diagnosis of Pneumocystis pneumonia. Kurume Med J 2008; 55:55-62.
112. Tumeh SS, Belville JS, Pugatch R, McNeil BJ. Ga-67 scintigraphy and computed tomography in the diagnosis of Pneumocystis carinii pneumonia in patients with AIDS. A prospective comparison. Clin Nucl Med 1992; 17:387-394.
113. Nakazato T, Mihara A, Sanada Y, et al. Pneumocystis jiroveci pneumonia detected by FDG-PET. Ann Hematol 2010; 89:839-840.
114. Win Z, Todd J, Al-Nahhas A. FDG-PET imaging in Pneumocystis carinii pneumonia. Clin Nucl Med 2005; 30:690-691. (Pubitemid 41361764)
115. Sojan SM, Chew G. Pneumocystis carinii pneumonia on F-18 FDG PET. Clin Nucl Med 2005; 30:763-764. (Pubitemid 41552131)
116. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-659. (Pubitemid 41170353)
117. Miyazaki T, Kohno S, Koga H, et al. G test, a new direct method for diagnosis of Candida infection: comparison with assays for beta-glucan and mannan antigen in a rabbit model of systemic candidiasis. J Clin Lab Anal 1992; 6:315-318.
118. Obayashi T, Yoshida M, Mori T, et al. Plasma (1-3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345:17-20.
119. Obayashi T, Yoshida M, Tamura H, et al. Determination of plasma (1->3)- beta-D-glucan: A new diagnostic aid to deep mycosis. J Med VetMycol 1992; 30:275-280.
120. Yuasa K, Goto H, Iguchi M, et al. Evaluation of the diagnostic value of the measurement of (1->3)-beta-D-glucan in patients with pulmonary aspergillosis. Respiration 1996; 63:78-83.
121. Yasuoka A, Tachikawa N, Shimada K, et al. (1->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3:197-199. (Pubitemid 26103756)
122. Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1 -> 3)-beta-Dglucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35:371-374.
123. Cuetara MS, Alhambra A, Chaves F, et al. Use of a serum (1->3)-beta-Dglucan assay for diagnosis and follow-up of Pneumocystis jiroveci pneumonia. Clin Infect Dis 2008; 47:1364-1366.
124. Pisculli ML, Sax PE. Use of a serum beta-glucan assay for diagnosis of HIVrelated Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results. Clin Infect Dis 2008; 46:1928-1930.
125. Marty FM, Koo S, Bryar J, Baden LR. (1->3)beta-D-Glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007; 147:70-72. (Pubitemid 351664641)
126. Damiani C, Le Gal S, Lejeune D, et al. Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol 2011; 49:2000-2002.
127. Held J, Koch MS, Reischl U, et al. Serum (1 -> 3)-beta-D-glucan measurement as an early indicator of Pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect 2011; 17:595-602.
128. Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum beta-Dglucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 2009; 48:195-202.
129. Persat F, Ranque S, Derouin F, et al. Contribution of the (1->3)-beta-Dglucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46:1009-1013. (Pubitemid 351379994)
130. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007; 131:1173-1180. (Pubitemid 46608722)
131. Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47:3871-3874.
132. Del Bono V, Mularoni A, Furfaro E, et al. Clinical evaluation of a (1,3)-beta-Dglucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol 2009; 16:1524-1526.
133. Shimizu A, Oka H, Matsuda T, Ozaki S. (1->3)-beta-D Glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005; 23:678-680. (Pubitemid 41300711)
134. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008; 46:1930-1931.
135. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349:2366-2367. (Pubitemid 37509754)